Trial Profile
A phase 2 study of SU011248 [sunitinib] in the treatment of patients with bevacizumab-refractory metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 06 Sep 2005 New trial record.